Lead


Lay summary
Lead: Biologically active synthetic polymers (BASP) decorated with small, tumor targeting peptides could be inexpensive alternatives for monoclonal antibodies. However, little is known about the pharmacokinetic profile of BASPs. This project will investigate the targeting capacity and pharmacokinetics of BASPs. Background: Targeted delivery of effector functions and moieties to diseased sites in the human body for diagnostic or therapeutic purposes is a hallmark of modern drug development. This is particularly true for cancerous diseases since cancer accounts still for more than 20 % of deaths in developed countries (www.cancer.org). Monoclonal antibodies (MAb) have become indispensable tools in this respect. However, the development and production of such macromolecules is extremely expensive and as a consequence such drugs are growing burden for the health system. Hence, less costly alternatives have to be developed and investigated which combine the positive biological and pharmacological features of antibodies with the lower costs of development of small molecules. Toward this goal the presented project aims to investigate the possibilty to use biologically active synthetic polymers (BASP) as an alternative to MAbs. The most sensitive and reliable way to investigate and characterize the pharmacokinetics of such BASPs in vitro and in vivo is to label them with a diagnostic radionuclide useful for positron emission tomography (PET) or single photon emission tomography (SPET). PET and SPET are used in the drug development process as well as for pre-clinical research.Specific Aims: In this project we propose to design tumor specific, radioactive BASP conjugates based on various polymer back-bones. We will chemically modify these polymers in order to decorate them with tumor targeting peptide derivative of bombesin. This G-protein coupled receptor is known to be overexpressed in a wide variety of human tumors such as prostate cancer and breast cancer among the most common cancers in men and women. We will label the BASPs with various diagnostic and therapeutic radionuclides such as Cu-64/67, Ga-67/68, Tc-99m and Lu-177 and characterize these compounds chemically as well as in vitro and in vivo.Expected Value of the Proposed Project: This proposal will provide an additional dynamic impulse towards the development and characterization of synthetic polymer for use in drug delivery and specifically for tumor targeting to improve the management of cancerous diseases in the future. If this project is successful we expect significant resonance from different areas of (targeted cancer-) research as well as from the pharmaceutical industry.